HER2-negative Breast Cancer Clinical Trials in Chicago, Illinois
10 recruitingChicago, Illinois
Showing 1–10 of 10 trials
Recruiting
Phase 1
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Metastatic Breast CancerHER2-negative Breast Cancer
University of Texas Southwestern Medical Center30 enrolled7 locationsNCT05029999
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521
Recruiting
Phase 2
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Breast CancerBreast NeoplasmsHER2-negative Breast Cancer+8 more
QuantumLeap Healthcare Collaborative5,000 enrolled42 locationsNCT01042379
Recruiting
Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
HR+/HER2-negative Breast Cancer
Totus Medicines241 enrolled18 locationsNCT05683418
Recruiting
Phase 2
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
HER2-negative Breast CancerHormone Receptor-Positive Breast CancerLocoregional Recurrence
Oana Danciu200 enrolled20 locationsNCT05467891
Recruiting
Phase 2
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
HER2-negative Breast Cancer Patients With Brain Metastases
Biostar Pharma, Inc.120 enrolled17 locationsNCT06764940
Recruiting
Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Breast NeoplasmsHER2-negative Breast CancerInvasive Breast Cancer+1 more
Atossa Therapeutics, Inc.87 enrolled15 locationsNCT05607004
Recruiting
Phase 2
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+1 more
Ana C Garrido-Castro, MD357 enrolled11 locationsNCT06533826
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1
PRE-I-SPY Phase I/Ib Oncology Platform Program
Triple-Negative Breast CancerMetastatic Breast CancerHER2-low Breast Cancer+18 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226